Kashimada Kenichi, Ishii Tomohiro, Nagasaki Keisuke, Ono Makoto, Tajima Toshihiro, Yokota Ichiro, Hasegawa Yukihiro
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Endocr J. 2015;62(3):277-82. doi: 10.1507/endocrj.EJ14-0377. Epub 2015 Jan 21.
Non-classical 21-hydroxylase deficiency (NC21-OHD) is a mild form of 21-hydroxylase deficiency lacking apparent symptoms of androgen excess at birth. Most NC21-OHD cases are diagnosed after the onset of puberty, while a substantial number of patients are not diagnosed during childhood. Previous studies have reported ethnic differences in the prevalence of NC21-OHD. To date, the clinical features of NC21-OHD in Japanese children have not been systemically reported. Thus, we performed 3 independent analyses: retrospective analyses of newborn screening in 2 major Japanese cities (Sapporo and Niigata) and a national surveillance collecting clinical information from pediatric endocrinologists throughout the country. During the last 10 years, one case of NC21-OHD was diagnosed by newborn screening in each city, resulting in incidences of 2.0 (95% confidence interval = 0.0-5.9) and 2.1 (0.0-6.2) per 1,000,000 in Sapporo and Niigata, respectively. We collected information from 85% of the 135 Councilors of Japanese Society of Pediatric Endocrinology. Fifteen NC21-OHD patients were diagnosed during childhood, resulting in the estimated prevalence of 0.58 (0.28-1.1) per 1,000,000. Eleven patients were discovered by newborn screening, 7 patients developed hyperandrogenism symptoms (2-8 years of age, median 7), and 9 patients were treated with hydrocortisone at the time of the survey. Ten out of 13 patients showed compound heterozygosity for the P30L mutation of CYP21A2. Our study suggests that the prevalence/incidence of NC21-OHD is lower than that in Western countries, and that the age for initial onset of androgen excess symptoms varies during the prepubertal period.
非经典型21-羟化酶缺乏症(NC21-OHD)是21-羟化酶缺乏症的一种轻度形式,出生时缺乏明显的雄激素过多症状。大多数NC21-OHD病例在青春期开始后被诊断出来,而相当一部分患者在儿童期未被诊断出来。先前的研究报告了NC21-OHD患病率的种族差异。迄今为止,日本儿童NC21-OHD的临床特征尚未得到系统报道。因此,我们进行了3项独立分析:对日本2个主要城市(札幌和新潟)新生儿筛查的回顾性分析,以及一项从全国儿科内分泌学家收集临床信息的全国性监测。在过去10年中,每个城市通过新生儿筛查诊断出1例NC21-OHD病例,札幌和新潟的发病率分别为每100万人口2.0(95%置信区间=0.0-5.9)和2.1(0.0-6.2)。我们从日本儿科内分泌学会135名委员中的85%收集了信息。15例NC21-OHD患者在儿童期被诊断出来,估计患病率为每100万人口0.58(0.28-1.1)。11例患者通过新生儿筛查被发现,7例患者出现高雄激素血症症状(2-8岁,中位数7岁),9例患者在调查时接受了氢化可的松治疗。13例患者中有10例显示CYP21A2基因P30L突变的复合杂合性。我们的研究表明,NC21-OHD的患病率/发病率低于西方国家,并且雄激素过多症状的初始发病年龄在青春期前有所不同。